Alternate-day dosing during buprenorphine treatment of opioid dependence.
L Amass, W K Bickel, S T Higgins...
https://pubmed.ncbi.nlm.nih.gov/8164503Completed
Phase 1
Age: 28Years - 45Years
All Genders
ID00000221
Alternate-Day Buprenorphine Administration. Phase I
Led by National Institute on Drug Abuse (NIDA) · Updated on 2005-06-24
N/A
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
National Institute on Drug Abuse (NIDA)
Lead Sponsor
U
University of Vermont
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.
CONDITIONS
Official Title
Alternate-Day Buprenorphine Administration. Phase I - 3
Who Can Participate
Age: 28Years - 45Years
All Genders
Eligibility Criteria
You may qualify if you...
Please contact site for information.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
Treatment Research Center
Burlington, Vermont, United States, 05401
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
N/A
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here